Journal list Promote Sponsor
verified SJR 1,09 · Q1 • database Scopus / SJR & Web of Science indexed
Expert Review of Anti-Infective Therapy
United Kingdom · Taylor and Francis Ltd.
workspace_premium Q1 — Microbiology lock Subscription

Expert Review of Anti-Infective Therapy

Expert Review of Anti-Infective Therapy is a journal indexed in SJR in Microbiology and Infectious Diseases with an H index of 103. It has a price of 4000 €. It has an SJR impact factor of 1,09 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,09.

Expert Review of Anti-Infective Therapy focuses its scope in these topics and keywords: hiv, worldwide, aeruginosa, treatment, remaining, producing, infection, spectrum, fumarate, colistin, ...

ISSN: 1478-7210
Publisher: Taylor and Francis Ltd.
Category: Microbiology
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
1,09 Q1
H-index 103
Acceptance rate pie_chart
26% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
4.000 € Subscription
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,09

H-index

103

Docs (year)

116

Docs 3y

391

Total refs

8146

Cites 3y

1722

Citable 3y

355

Cites/Doc 2y

3.9

Ref/Doc

70.22

Immediate OA

4000 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

FAQs